4-((4-methylpiperazin-1-yl)methyl)-3-chloro-benzoic acid | 895519-99-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((4-methylpiperazin-1-yl)methyl)-3-chloro-benzoic acid
• 英文别名: 3-chloro-4-((4-methylpiperazin-1-yl)methyl)benzoic acid；3-chloro-4-[(4-methylpiperazin-1-yl)methyl]benzoic acid
• CAS: 895519-99-0
• 化学式: C₁₃H₁₇ClN₂O₂
• mdl: MFCD23162843
• 分子量: 268.743
• InChiKey: ONQRZOWXNWPTHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((4-methylpiperazin-1-yl)methyl)-3-chloro-benzoic acid 在 吡啶 、 氯化亚砜 作用下， 生成 3-chloro-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]phenyl}benzamide
  参考文献：
  名称：

  Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

  摘要：

  A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.042
• 作为产物：
  描述：

  4-溴甲基-3-氯苯甲酸乙酯 在 sodium hydroxide 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 生成 4-((4-methylpiperazin-1-yl)methyl)-3-chloro-benzoic acid
  参考文献：
  名称：

  Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

  摘要：

  A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bcr-Abl-positive leukemia cell line K562. About ten 3-halogenated and 3-trifluoromethylated benzamide derivatives were identified as highly potent Bcr-Abl kinase inhibitors. One of these, NS-187 (9b), is a promising new candidate Bcr-Abl inhibitor for the therapy of STI-571-resistant chronic myeloid leukemia. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.042

文献信息

• Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof
  申请人：Sun Piaoyang

  公开号：US20080312251A1

  公开（公告）日：2008-12-18

  The present invention provides aminopyrimidine compounds of formula (I) and their salts, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Q, Z, L, m, n are defined as the description, the methods for preparation thereof, the uses thereof and the pharmaceutical compositions comprising the effective amount of compounds of formula (I). The compounds of formula (I) and their salts can be used as protein kinase inhibitors.

  本发明提供了式（I）的氨基嘧啶化合物及其盐，其中R1，R2，R3，R4，R5，R6，Q，Z，L，m，n如所述，其制备方法，其用途以及包含式（I）化合物的有效量的药物组合物。式（I）的化合物及其盐可用作蛋白激酶抑制剂。
• SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Lyssikatos Joseph P.

  公开号：US20120322785A1

  公开（公告）日：2012-12-20

  The invention provides novel compounds having the general formula: wherein X 1 is N or N + O − , and one of X 2 , X 3 and X 4 is N or N + —O − and the remainder of X 2 , X 3 and X 4 is C. R 2 , R 3 , R 4 , R 5 , R 6 . A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

  该发明提供了新颖的化合物，其具有以下一般式：其中X1为N或N+O−，而X2、X3和X4中的一个为N或N+—O−，而X2、X3和X4的其余部分为C。R2、R3、R4、R5、R6、A、B和Y如本文所述。此外，还进一步描述了I式化合物的组合物和使用方法。
• Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
  申请人：Lyssikatos Joseph P.

  公开号：US08623889B2

  公开（公告）日：2014-01-07

  The invention provides novel compounds having the general formula: wherein X1 is N or N+O−, and one of X2, X3 and X4 is N or N+—O− and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

  这项发明提供了具有一般式的新化合物： 其中X1是N或N+O−，X2、X3和X4中的一个是N或N+—O−，其余的X2、X3和X4是C。R2、R3、R4、R5、R6、A、B和Y如本文所述。此外，本文还进一步描述了公式I的组成物、化合物和使用方法。
• Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof
  申请人：Genentech, Inc.

  公开号：US20160060262A1

  公开（公告）日：2016-03-03

  The invention provides novel compounds having the general formula: wherein X 1 is N or N + O − , and one of X 2 , X 3 and X 4 is N or N + —O − and the remainder of X 2 , X 3 and X 4 is C. R 2 , R 3 , R 4 , R 5 , R 6 . A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

  该发明提供了具有一般式的新化合物：其中X1是N或N+O−，而X2、X3和X4中的一个是N或N+—O−，而X2、X3和X4的其余部分是C。 R2、R3、R4、R5、R6、A、B和Y如本文所述。此外，本文还进一步描述了配方I的化合物和使用方法。
• [EN] SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AZOTÉS 6,6-CONDENSÉS SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012080284A3

  公开（公告）日：2012-09-07